KAS
INDV icon

Kemnay Advisory Services’s Indivior Pharmaceuticals INDV Stock Holding History

Kemnay Advisory Services’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.8K Sell
977
-3,331
-77% -$110K ﹤0.01% 449
2025
Q4 		$155K Buy
+4,308
New +$132K 0.02% 65

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kemnay Advisory Services's INDV Position: Q1 2026 in Review

Kemnay Advisory Services reduced its Indivior Pharmaceuticals (INDV) stake by 77% in Q1 2026, selling an estimated $110K and leaving 977 shares worth $29.8K. The position accounts for ﹤0.01% of the portfolio, ranked #449.

Kemnay Advisory Services first reported a position in INDV in Q4 2025 and has held it in 2 quarters since. The position peaked at $155K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Kemnay Advisory Services held 977 shares of Indivior Pharmaceuticals worth $29.8K as of Q1 2026.
  • Kemnay Advisory Services sold 3,331 Indivior Pharmaceuticals shares in Q1 2026, an estimated $110K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #449 holding.
  • Kemnay Advisory Services first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Kemnay Advisory Services's Indivior Pharmaceuticals position peaked at $155K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.